TerrAscend has operations in the US, Canada and Europe. US operations encompass vertically integrated operations in California, New Jersey, and Pennsylvania, along with licensed manufacturing in Maryland. TerrAscend is closely involved in every medical and recreational facet of the cannabis markets, working across all aspects of the business, from growing and processing to retailing and advertising. In June, the company launched its Type Tree-branded product portfolio in the state of Maryland, and previously, in May, TerrAscend opened a second medical cannabis dispensary in New Jersey. The new facility within the Backyard State is 6,500 square feet and offers a full range of TerrAscend brand medical cannabis products. TerrAscend will report its 2Q21 figures later this week, but a look at the company's latest efficiency, in light of its growth actions, could also be informative in the lead up to the quarterly launch. In the first quarter, TRSSF reported $ 53.4 million in gross web sales, an increase of 106% in 12 months, and noted that cash flow from operations increased from a loss of $ 800K in 1Q20 to a profit of $ 13 million.
While the US market is fragmented into state-grade entities and somewhat hampered by the lack of a federal move toward legalization, it remains substantial. Gross sales of legalized cannabis in the US reached $ 17.5 billion last year, and have been $ 12.9 billion in 2019. Business analysts anticipate that sales of cannabis within the US They will exceed $ 41 billion by 2026. These figures dwarf their equivalents in Canada, the place even with full legalization, the country's comparatively small population has kept its gross cannabis sales at just $ 2.6 billion over the past 12 months, with a forecast for 2026 of $ 6.4 billion.. Clearly, despite the headwinds, investors should wait long and sell out in the US cannabis markets, so let's take a look at some US cannabis companies. According to the TipRanks database, these are Sturdy Buy shares, with a one-year upside potential of at least 70%. Let's find out what else they have to offer buyers. We will start with TerrAscend, a cannabis company that has managed to cross borders.
99% of the current share price of $ 8.14. Then there is Curaleaf, one of the leading cannabis firms in the US. A look at the numbers reveals how Curaleaf has come to take a leadership position in the US cannabis market.From its Massachusetts headquarters, the company maintains a presence in 23 states, with 23 grow facilities, 30 processing sites. and more than a hundred dispensaries. Curaleaf's focus is on states with large populations and restricted cannabis licenses, including Florida, Illinois, Massachusetts, New Jersey, New York, and Pennsylvania. The company has a trading-leading market capitalization of $ 8.17 billion. The company's revenue has increased steadily from quarter to quarter. The top line of sales for 2Q21 in the United States, of $ 306.3 million, was a document of the organization and a gain of 135% compared to 2Q20. Complete revenue, along with worldwide gross sales, came to $ 312 million. Curaleaf has been driving its revenue growth with a continued expansion of its production and retail presence. May's company acquired the 66-acre Los Sueños Outdoor facility in Colorado, one of the largest development websites of its kind in the US In addition, Curaleaf activated nearly 250,000 grow plants of ' flower canopy 'in 1H21, and it plans to bring another 40,000 square feet online over the course of the second half of the year. The company now has approximately 2 million square feet of development capacity. At the retail entrance, Curaleaf opened new stores in Illinois, Pennsylvania, New Jersey and Maine. Masking CURLF's stock for Cowen, five-star analyst Vivien Azer sees a clear path for accelerated sales progress. Looking to the back half, the company may open its third New Jersey dispensary this month, while increasing capacity to be ready for the introduction of adult use.
The North American cannabis markets have been doing this since 2018, when Canada enacted full national legalization of the plant and its derivatives. Since then, the Canadian cannabis industry has exploded. The situations are completely different, but still optimistic, south of the border, where the United States remains a patchwork of legal regimes. However, the US federal regulation lists cannabis as a administered substance, a subject of drug law enforcement by law enforcement agencies. At the same time, 18 US states. They have enacted full legalization, along with every recreational and medical use, while others have some form of medical use legalization or general decriminalization. In total, 37 states have some type of legalized cannabis market. When the Biden Administration entered the workplace, it was hypothesized that the new democratically administered Congress would be transferred to enact the legalization of cannabis at the federal level. The contingencies of politics and the world, however, have derailed those hopes. With Democratic control of the Senate dependent on Vice President Harris 'runoff vote, and the Democratic majority within the Home down to just a few seats, the Party and Administration have no votes to spare in Congress, and for now, they can' To See How "Boosting cannabis," the country faces high inflation, a labor shortage, a $ 3.5 trillion spending plan that works through the legislature, and occasions in Afghanistan.
Blood, breath and urine. These are the holy trinity for determining alcohol intoxication, but they are nearly useless when measuring the amount of THC in your system thanks to the molecule's ability to stay current in bodily fluids for up to a month after consumption. Nonetheless, a technological breakthrough from Stanford University could soon allow law enforcement to pinpoint how dull you are as fast as they pull you over. Moderately than the three common fluids, the Stanford "potalyzer" measures the amount of THC in your saliva. It is reportedly correct enough to detect zero to 50 nanograms of THC per milliliter of saliva. The system, developed by Dr. Shan Wang and his team, uses magnetic biosensors to detect the THC molecules present in saliva. The technology really grew out of Wang's earlier researchon in vitro diagnosis of most cancers and magnetic information storage. The control itself involves first mixing the saliva. sample with antibodies that bind to THC molecules and act as markers.